These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38512900)

  • 1. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
    Sriphoosanaphan S; Pantumongkol W; Kulpeng W; Charonpongsuntorn C; Tanwandee T; Sukeepaisarnjaroen W; Sobhonslidsuk A; Tangkijvanich P
    PLoS One; 2024; 19(3):e0300327. PubMed ID: 38512900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
    Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
    Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
    Chee CE; Khara JS; Cheong J; Fong J; Sivanesan S; Choy JY; Hu M; Viswambaram A; Toh HC
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):631-641. PubMed ID: 38776431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis.
    Zhao M; Pan X; Yin Y; Hu H; Wei J; Bai Z; Tang W
    Front Public Health; 2022; 10():869960. PubMed ID: 35493395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wen F; Huang P; Wu Q; Yang Y; Zhou K; Zhang M; Li Q
    Cancer Med; 2024 Aug; 13(16):e70094. PubMed ID: 39149756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Li Y; Liang X; Li H; Chen X
    Cancer; 2022 Nov; 128(22):3995-4003. PubMed ID: 36111952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand.
    Kittiratchakool N; Kulpokin D; Chanjam C; Vilaiyuk S; Charuvanij S; Phongsamart G; Khaosut P; Tanya M; Nanagara R; Nantapaisarn S; Leelahavarong P
    BMJ Open; 2020 Sep; 10(9):e037588. PubMed ID: 32933962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
    Zhou T; Cao Y; Wang X; Yang L; Wang Z; Ma A; Li H
    Adv Ther; 2022 May; 39(5):2165-2177. PubMed ID: 35296994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
    Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
    Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
    Permsuwan U; Thongprasert S; Sirichanchuen B
    Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
    Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
    JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
    Zhou T; Wang X; Cao Y; Yang L; Wang Z; Ma A; Li H
    BMC Health Serv Res; 2022 Nov; 22(1):1367. PubMed ID: 36397064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of an alcohol policy in Thailand: a case study of a random breath testing intervention.
    Vichitkunakorn P; Khampang R; Leelahavarong P; Nontarak J; Assanangkornchai S
    BMC Health Serv Res; 2024 Jun; 24(1):739. PubMed ID: 38886718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
    Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
    J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
    Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
    J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.